Matches in SemOpenAlex for { <https://semopenalex.org/work/W4205400526> ?p ?o ?g. }
Showing items 1 to 84 of
84
with 100 items per page.
- W4205400526 endingPage "TPS373" @default.
- W4205400526 startingPage "TPS373" @default.
- W4205400526 abstract "TPS373 Background: Esophageal cancer is the eighth most common cancer type and the sixth leading cause of cancer-related death worldwide, and esophageal squamous cell carcinoma (ESCC) is the most common type of esophageal cancer. For patients with locally advanced, unresectable ESCC (AJCC 8th Stage II–IVA), definitive chemoradiotherapy (dCRT) is the current standard of care; however, up to half of patients will experience disease progression within two years of dCRT, and overall survival rates remain suboptimal. The combination of immune checkpoint inhibitors with CRT has demonstrated synergistic antitumor activity in pre-clinical models, and recent clinical data has demonstrated clinical benefit of combined programmed cell death-1 inhibition and preoperative CRT in patients with locally advanced ESCC. KUNLUN (NCT04550260) is a Phase 3, multicenter, global study evaluating the efficacy and safety of durvalumab, a programmed cell death ligand-1 (PD-L1) inhibitor, given concurrently with, and after, dCRT in patients with locally advanced, unresectable ESCC. Methods: Approximately 600 patients will be randomized 2:1 to receive either durvalumab with dCRT (cisplatin plus fluorouracil or cisplatin plus capecitabine, with a total dose of 50–64 Gy radiation), followed by durvalumab for up to approximately 24 months, or placebo with dCRT, followed by placebo for up to approximately 24 months. Eligible patients will have histologically or cytologically confirmed ESCC, and present with locally advanced, unresectable ESCC that is deemed suitable for dCRT. Patients must have an Eastern Cooperative Oncology Group performance status of 0 or 1, and have not received prior anti-cancer treatment. The co-primary endpoint of the study is progression-free survival according to RECIST v1.1 as assessed by blinded independent central review in all randomized patients and in patients with PD-L1-high tumors. Additional endpoints include overall survival and safety. Study enrollment is ongoing. Funding: This study was sponsored by AstraZeneca. References: Hong MH, et al. J Clin Oncol 2019;37(15 suppl). Abs 4027. Clinical trial information: NCT04550260." @default.
- W4205400526 created "2022-01-26" @default.
- W4205400526 creator A5013542496 @default.
- W4205400526 creator A5027610105 @default.
- W4205400526 creator A5036672833 @default.
- W4205400526 creator A5038721807 @default.
- W4205400526 creator A5063661303 @default.
- W4205400526 creator A5065482772 @default.
- W4205400526 creator A5078543853 @default.
- W4205400526 creator A5080347139 @default.
- W4205400526 creator A5081006934 @default.
- W4205400526 creator A5082832235 @default.
- W4205400526 creator A5091692711 @default.
- W4205400526 date "2022-02-01" @default.
- W4205400526 modified "2023-10-01" @default.
- W4205400526 title "A phase 3 randomized, double-blind, placebo-controlled, multicenter, global study of durvalumab with and after chemoradiotherapy in patients with locally advanced, unresectable esophageal squamous cell carcinoma: KUNLUN." @default.
- W4205400526 doi "https://doi.org/10.1200/jco.2022.40.4_suppl.tps373" @default.
- W4205400526 hasPublicationYear "2022" @default.
- W4205400526 type Work @default.
- W4205400526 citedByCount "6" @default.
- W4205400526 countsByYear W42054005262022 @default.
- W4205400526 countsByYear W42054005262023 @default.
- W4205400526 crossrefType "journal-article" @default.
- W4205400526 hasAuthorship W4205400526A5013542496 @default.
- W4205400526 hasAuthorship W4205400526A5027610105 @default.
- W4205400526 hasAuthorship W4205400526A5036672833 @default.
- W4205400526 hasAuthorship W4205400526A5038721807 @default.
- W4205400526 hasAuthorship W4205400526A5063661303 @default.
- W4205400526 hasAuthorship W4205400526A5065482772 @default.
- W4205400526 hasAuthorship W4205400526A5078543853 @default.
- W4205400526 hasAuthorship W4205400526A5080347139 @default.
- W4205400526 hasAuthorship W4205400526A5081006934 @default.
- W4205400526 hasAuthorship W4205400526A5082832235 @default.
- W4205400526 hasAuthorship W4205400526A5091692711 @default.
- W4205400526 hasConcept C121608353 @default.
- W4205400526 hasConcept C126322002 @default.
- W4205400526 hasConcept C142724271 @default.
- W4205400526 hasConcept C143998085 @default.
- W4205400526 hasConcept C203092338 @default.
- W4205400526 hasConcept C204787440 @default.
- W4205400526 hasConcept C27081682 @default.
- W4205400526 hasConcept C2777701055 @default.
- W4205400526 hasConcept C2777742743 @default.
- W4205400526 hasConcept C2778424827 @default.
- W4205400526 hasConcept C2779742542 @default.
- W4205400526 hasConcept C2780030458 @default.
- W4205400526 hasConcept C31760486 @default.
- W4205400526 hasConcept C535046627 @default.
- W4205400526 hasConcept C71924100 @default.
- W4205400526 hasConceptScore W4205400526C121608353 @default.
- W4205400526 hasConceptScore W4205400526C126322002 @default.
- W4205400526 hasConceptScore W4205400526C142724271 @default.
- W4205400526 hasConceptScore W4205400526C143998085 @default.
- W4205400526 hasConceptScore W4205400526C203092338 @default.
- W4205400526 hasConceptScore W4205400526C204787440 @default.
- W4205400526 hasConceptScore W4205400526C27081682 @default.
- W4205400526 hasConceptScore W4205400526C2777701055 @default.
- W4205400526 hasConceptScore W4205400526C2777742743 @default.
- W4205400526 hasConceptScore W4205400526C2778424827 @default.
- W4205400526 hasConceptScore W4205400526C2779742542 @default.
- W4205400526 hasConceptScore W4205400526C2780030458 @default.
- W4205400526 hasConceptScore W4205400526C31760486 @default.
- W4205400526 hasConceptScore W4205400526C535046627 @default.
- W4205400526 hasConceptScore W4205400526C71924100 @default.
- W4205400526 hasIssue "4_suppl" @default.
- W4205400526 hasLocation W42054005261 @default.
- W4205400526 hasOpenAccess W4205400526 @default.
- W4205400526 hasPrimaryLocation W42054005261 @default.
- W4205400526 hasRelatedWork W2097249378 @default.
- W4205400526 hasRelatedWork W2168952713 @default.
- W4205400526 hasRelatedWork W2249625608 @default.
- W4205400526 hasRelatedWork W2947816590 @default.
- W4205400526 hasRelatedWork W3200621203 @default.
- W4205400526 hasRelatedWork W4226103262 @default.
- W4205400526 hasRelatedWork W4281840423 @default.
- W4205400526 hasRelatedWork W4310753259 @default.
- W4205400526 hasRelatedWork W4362584161 @default.
- W4205400526 hasRelatedWork W4379280921 @default.
- W4205400526 hasVolume "40" @default.
- W4205400526 isParatext "false" @default.
- W4205400526 isRetracted "false" @default.
- W4205400526 workType "article" @default.